| 1227935-84-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• CAS: 1227935-84-3
• 化学式: C₁₃H₁₄O₄
• 分子量: 234.252
• InChiKey: XIAFDZPVZSUPSE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.38
• 重原子数：
  17.0
• 可旋转键数：
  0.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  66.76
• 氢给体数：
  2.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  在 盐酸 、 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 水 、 丙酮 为溶剂， 反应 2.0h， 生成 C₁₃H₁₄O₃
  参考文献：
  名称：

  Discovery of Small Molecules as Multi-Toll-like Receptor Agonists with Proinflammatory and Anticancer Activities

  摘要：

  Therapies based on activation of multiple Toll-like receptors (TLRs) may offer superior therapeutic profiles than that of single TLR activation. To, discover new small molecules that could activate multiple TLRs, we performed a cell-based high-throughput, screening of a small-molecule library based on TLR3-mediated NF-kappa B activation. Subsequent structural optimization and counterscreening of other TLRs produced the first small molecule 17e (CU-CPT17e), capable of simultaneously activating TLRs 3) 8, and 9. Biochemical studies demonstrated that 17e could induce a strong immune response via the production of various cytokines in human monocytic THP-1 cells. Furthermore, 17e inhibited the proliferation of HeLa cancer cells by triggering apoptosis and arresting the-cell. cycle at the S phase. These results Showcase potential therapeutic applications of 17e it both vaccine adjuvants and anticancer therapies based on multi-TLR activation.

  DOI：

  10.1021/acs.jmedchem.7b00419
• 作为产物：
  描述：

  2'-羟基-4',5'-二甲氧基苯乙酮 在 四氢吡咯 、 三溴化硼 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Discovery of Small Molecules as Multi-Toll-like Receptor Agonists with Proinflammatory and Anticancer Activities

  摘要：

  Therapies based on activation of multiple Toll-like receptors (TLRs) may offer superior therapeutic profiles than that of single TLR activation. To, discover new small molecules that could activate multiple TLRs, we performed a cell-based high-throughput, screening of a small-molecule library based on TLR3-mediated NF-kappa B activation. Subsequent structural optimization and counterscreening of other TLRs produced the first small molecule 17e (CU-CPT17e), capable of simultaneously activating TLRs 3) 8, and 9. Biochemical studies demonstrated that 17e could induce a strong immune response via the production of various cytokines in human monocytic THP-1 cells. Furthermore, 17e inhibited the proliferation of HeLa cancer cells by triggering apoptosis and arresting the-cell. cycle at the S phase. These results Showcase potential therapeutic applications of 17e it both vaccine adjuvants and anticancer therapies based on multi-TLR activation.

  DOI：

  10.1021/acs.jmedchem.7b00419

文献信息

• Development of a Benzopyran-Containing Androgen Receptor Antagonist to Treat Antiandrogen-Resistant Prostate Cancer
  作者：Sangmi Oh、Hye Jin Nam、Jongmin Park、Sung Hee Beak、Seung Bum Park

  DOI：10.1002/cmdc.200900509

  日期：2010.4.6